Federated Hermes
MRNA icon

Federated Hermes’s Moderna MRNA Stock Holding History

Federated Hermes’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$126M Sell
1,794,778
-182,301
-9% -$9.43M 0.18% 131
2026
Q1 		$100M Sell
1,977,079
-201,458
-9% -$9.4M 0.16% 139
2025
Q4 		$64.2M Sell
2,178,537
-600,464
-22% -$16.3M 0.11% 225
2025
Q3 		$71.8M Sell
2,779,001
-90,270
-3% -$2.52M 0.13% 192
2025
Q2 		$79.2M Buy
2,869,271
+2,251,497
+364% +$59.3M 0.15% 172
2025
Q1 		$17.5M Buy
617,774
+617,368
+152,061% +$21.9M 0.04% 428
2024
Q4 		$16.9K Sell
406
-1,844
-82% -$88.1K ﹤0.01% 1785
2024
Q3 		$150K Buy
2,250
+297
+15% +$27.3K ﹤0.01% 1529
2024
Q2 		$232K Buy
1,953
+104
+6% +$13.2K ﹤0.01% 1452
2024
Q1 		$197K Sell
1,849
-5
-0.3% -$504 ﹤0.01% 1495
2023
Q4 		$184K Sell
1,854
-3,126
-63% -$263K ﹤0.01% 1524
2023
Q3 		$514K Sell
4,980
-130
-3% -$14.5K ﹤0.01% 1323
2023
Q2 		$621K Sell
5,110
-54,342
-91% -$7.25M ﹤0.01% 1301
2023
Q1 		$9.13M Sell
59,452
-67,963
-53% -$11.2M 0.02% 571
2022
Q4 		$22.9M Sell
127,415
-42,798
-25% -$7M 0.06% 350
2022
Q3 		$20.1M Buy
170,213
+111,644
+191% +$16.9M 0.06% 379
2022
Q2 		$8.37M Sell
58,569
-64,027
-52% -$9.15M 0.02% 586
2022
Q1 		$21.1M Buy
122,596
+119,346
+3,672% +$20.1M 0.05% 427
2021
Q4 		$826K Sell
3,250
-736,454
-100% -$215M ﹤0.01% 1341
2021
Q3 		$285M Sell
739,704
-803,480
-52% -$296M 0.54% 25
2021
Q2 		$363M Sell
1,543,184
-45,970
-3% -$8.22M 0.68% 19
2021
Q1 		$208M Sell
1,589,154
-263,727
-14% -$38.2M 0.4% 47
2020
Q4 		$194M Buy
1,852,881
+93,688
+5% +$9.48M 0.4% 52
2020
Q3 		$124M Sell
1,759,193
-1,794,611
-50% -$125M 0.29% 77
2020
Q2 		$228M Sell
3,553,804
-1,129,783
-24% -$61.9M 0.56% 35
2020
Q1 		$140M Buy
4,683,587
+4,682,416
+399,865% +$108M 0.41% 44
2019
Q4 		$23K Buy
+1,171
New +$20.8K ﹤0.01% 1818

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Federated Hermes's MRNA Position: Q2 2026 in Review

Federated Hermes reduced its Moderna (MRNA) stake by 9.2% in Q2 2026, selling an estimated $9.43M and leaving 1,794,778 shares worth $126M. The position accounts for 0.18% of the portfolio, ranked #131.

Federated Hermes first reported a position in MRNA in Q4 2019 and has held it in 27 quarters since. The position peaked at $363M in Q2 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Federated Hermes held 1,794,778 shares of Moderna worth $126M as of Q2 2026.
  • Federated Hermes sold 182,301 Moderna shares in Q2 2026, an estimated $9.43M.
  • Moderna made up 0.18% of Federated Hermes's portfolio in Q2 2026, its #131 holding.
  • Federated Hermes first reported a position in Moderna in Q4 2019 and has held it in 27 quarters since.
  • Federated Hermes's Moderna position peaked at $363M in Q2 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.